Nonalcoholic fatty liver disease is the most common chronic liver disease and may progress to nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The molecular determinants of this pathogenic progression, however, remain largely undefined. Since liver tumorigenesis is driven by apoptosis, we examined the effect of overt hepatocyte apoptosis in a mouse model of NASH using mice lacking myeloid cell leukemia 1 (Mcl1), a pro-survival member of the BCL-2 protein family. Hepatocyte-specific Mcl1 knockout (Mcl1∆hep) mice and control littermates were fed chow or FFC (high saturated fat, fructose, and cholesterol) diet, which induces NASH, for 4 and 10 months. Thereafter, liver injury, inflammation, fibrosis, and tumor development were evaluated biochemically and histologically. Mcl1∆hep mice fed with the FFC diet for 4 months displayed a marked increase in liver injury, hepatocyte apoptosis, hepatocyte proliferation, macrophage-associated liver inflammation, and pericellular fibrosis in contrast to chow-fed Mcl1∆hep and FFC diet-fed Mcl1-expressing littermates. After 10 months of feeding, 78% of FFC diet-fed Mcl1∆hep mice developed liver tumors compared to 38% of chow-fed mice of the same genotype. Tumors in FFC diet-fed Mcl1∆hep mice were characterized by cytologic atypia, altered liver architecture, immunopositivity for glutamine synthetase, and histologically qualified as HCC. In conclusion, this study provides evidence that excessive hepatocyte apoptosis exacerbates the NASH phenotype with enhancement of tumorigenesis in mice.

Department of Chemistry and Biochemistry Mendel University in Brno Brno Czech Republic

Department of Pathology and Molecular Pathology University and University Hospital Zurich Zurich Switzerland

Division of Chronic Inflammation and Cancer German Cancer Research Center Heidelberg Germany

Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN USA

Institute of Clinical Biochemistry and Diagnostics University Hospital Hradec Kralove Hradec Kralove Czech Republic

Institute of Molecular Cancer Research University Zurich Zurich Switzerland

Zobrazit více v PubMed

Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. doi: 10.1002/hep.28431. PubMed DOI

Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut. 2018;67:963–972. doi: 10.1136/gutjnl-2017-315691. PubMed DOI PMC

Fingas CD, Best J, Sowa J-P, Canbay A. Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma. Clin. Liver Dis. 2016;8:119–122. doi: 10.1002/cld.585. PubMed DOI PMC

Wolf MJ, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26:549–564. doi: 10.1016/j.ccell.2014.09.003. PubMed DOI

Malehmir M, et al. Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat. Med. 2019;25:641–655. doi: 10.1038/s41591-019-0379-5. PubMed DOI

Hirsova P, Guicciardi ME, Gores GJ. Proapoptotic signaling induced by deletion of receptor-interacting kinase 1 and TNF receptor-associated factor 2 results in liver carcinogenesis. Hepatology. 2017;66:983–985. doi: 10.1002/hep.29272. PubMed DOI PMC

Vick B, et al. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology. 2009;49:627–636. doi: 10.1002/hep.22664. PubMed DOI PMC

Weber A, et al. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology. 2010;51:1226–1236. doi: 10.1002/hep.23479. PubMed DOI PMC

Boege Y, et al. A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development. Cancer Cell. 2017;32:342–359 e310. doi: 10.1016/j.ccell.2017.08.010. PubMed DOI PMC

Schneider AT, et al. RIPK1 suppresses a TRAF2-dependent pathway to liver cancer. Cancer Cell. 2017;31:94–109. doi: 10.1016/j.ccell.2016.11.009. PubMed DOI

Bettermann K, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010;17:481–496. doi: 10.1016/j.ccr.2010.03.021. PubMed DOI

Luedde T, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119–132. doi: 10.1016/j.ccr.2006.12.016. PubMed DOI

Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol. Gastroenterol. Hepatol. 2015;1:17–27. doi: 10.1016/j.jcmgh.2014.11.005. PubMed DOI PMC

Charlton M, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am. J. Physiol. Gastrointest. Liver Physiol. 2011;301:G825–G834. doi: 10.1152/ajpgi.00145.2011. PubMed DOI PMC

Hirsova P, Ibrahim SH, Bronk SF, Yagita H, Gores GJ. Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS ONE. 2013;8:e70599. doi: 10.1371/journal.pone.0070599. PubMed DOI PMC

Hirsova P, et al. TRAIL deletion prevents liver, but not adipose tissue, inflammation during murine diet-induced obesity. Hepatol. Commun. 2017;1:648–662. doi: 10.1002/hep4.1069. PubMed DOI PMC

Tomita, K. et al. Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis. JCI Insight10.1172/jci.insight.94488 (2017). PubMed PMC

Hirsova Petra, Ibrahim Samar H., Krishnan Anuradha, Verma Vikas K., Bronk Steven F., Werneburg Nathan W., Charlton Michael R., Shah Vijay H., Malhi Harmeet, Gores Gregory J. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. Gastroenterology. 2016;150(4):956–967. doi: 10.1053/j.gastro.2015.12.037. PubMed DOI PMC

Guo Q, et al. Integrin beta1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. J. Hepatol. 2019;71:1193–1205. doi: 10.1016/j.jhep.2019.07.019. PubMed DOI PMC

Gutierrez Sanchez LH, et al. Perinatal nutritional reprogramming of the epigenome promotes subsequent development of nonalcoholic steatohepatitis. Hepatol. Commun. 2018;2:1493–1512. doi: 10.1002/hep4.1265. PubMed DOI PMC

Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal models of nonalcoholic steatohepatitis: eat, delete, and inflame. Dig. Dis. Sci. 2016;61:1325–1336. doi: 10.1007/s10620-015-3977-1. PubMed DOI PMC

Krishnan A, et al. A longitudinal study of whole body, tissue and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am. J. Physiol. Gastrointest. Liver Physiol. 2017;00213:02016. PubMed PMC

Tomita K, et al. CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Sci. Rep. 2016;6:28786. doi: 10.1038/srep28786. PubMed DOI PMC

Brunt EM, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820. doi: 10.1002/hep.24127. PubMed DOI PMC

Tacke F. Targeting hepatic macrophages to treat liver diseases. J. Hepatol. 2017;66:1300–1312. doi: 10.1016/j.jhep.2017.02.026. PubMed DOI

Kazankov K, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 2019;16:145–159. doi: 10.1038/s41575-018-0082-x. PubMed DOI

Koyama Y, Brenner DA. Liver inflammation and fibrosis. J. Clin. Invest. 2017;127:55–64. doi: 10.1172/JCI88881. PubMed DOI PMC

Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 2014;14:181–194. doi: 10.1038/nri3623. PubMed DOI

Friemel J, et al. Characterization of HCC mouse models: towards an etiology-oriented subtyping approach. Mol. Cancer Res. 2019;17:1493–1502. doi: 10.1158/1541-7786.MCR-18-1045. PubMed DOI

Cairo S, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008;14:471–484. doi: 10.1016/j.ccr.2008.11.002. PubMed DOI

Idrissova L, et al. TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. J. Hepatol. 2015;62:1156–1163. doi: 10.1016/j.jhep.2014.11.033. PubMed DOI PMC

Hirsova P, Gores GJ. Reply. Cell Mol. Gastroenterol. Hepatol. 2015;1:265–266. doi: 10.1016/j.jcmgh.2015.03.001. PubMed DOI PMC

Hirsova P, Ibrabim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J. Lipid Res. 2016;57:1758–1770. doi: 10.1194/jlr.R066357. PubMed DOI PMC

Hikita H, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology. 2009;50:1217–1226. doi: 10.1002/hep.23126. PubMed DOI PMC

Takehara T, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. 2004;127:1189–1197. doi: 10.1053/j.gastro.2004.07.019. PubMed DOI

Canbay A, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest. 2003;83:655–663. doi: 10.1097/01.LAB.0000069036.63405.5C. PubMed DOI

Ibrahim SH, et al. Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. Hepatology. 2016;63:731–744. doi: 10.1002/hep.28252. PubMed DOI PMC

Henry CM, Martin SJ. Caspase-8 acts in a non-enzymatic role as a scaffold for assembly of a pro-inflammatory “FADDosome” complex upon TRAIL stimulation. Mol. Cell. 2017;65:715–729 e715. doi: 10.1016/j.molcel.2017.01.022. PubMed DOI

Cullen SP, et al. Fas/CD95-induced chemokines can serve as “Find-Me” signals for apoptotic cells. Mol. Cell. 2013;49:1034–1048. doi: 10.1016/j.molcel.2013.01.025. PubMed DOI

Tomita K, et al. Mixed lineage kinase 3 mediates the induction of CXCL10 by a STAT1-dependent mechanism during hepatocyte lipotoxicity. J. Cell Biochem. 2017;118:3249–3259. doi: 10.1002/jcb.25973. PubMed DOI PMC

Labi V, Erlacher M. How cell death shapes cancer. Cell Death Dis. 2015;6:e1675. doi: 10.1038/cddis.2015.20. PubMed DOI PMC

Febbraio MA, et al. Preclinical models for studying NASH-driven HCC: how useful are they? Cell Metab. 2019;29:18–26. doi: 10.1016/j.cmet.2018.10.012. PubMed DOI PMC

Tsuchida T, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J. Hepatol. 2018;69:385–395. doi: 10.1016/j.jhep.2018.03.011. PubMed DOI PMC